dc.contributor.author | Ovejero-Benito, María C. | |
dc.contributor.author | Prieto-Pérez, Rocío | |
dc.contributor.author | Llamas-Velasco, Mar | |
dc.contributor.author | Muñoz-Aceituno, Ester | |
dc.contributor.author | Reolid, Alejandra | |
dc.contributor.author | Saiz-Rodríguez, Miriam | |
dc.contributor.author | Belmonte, Carmen | |
dc.contributor.author | Román, Manuel | |
dc.contributor.author | Ochoa Mazarro, María Dolores | |
dc.contributor.author | Talegón, María | |
dc.contributor.author | Cabaleiro, Teresa | |
dc.contributor.author | Daudén Tello, Esteban | |
dc.contributor.author | Abad Santos, Francisco | |
dc.contributor.other | UAM. Departamento de Farmacología | es_ES |
dc.contributor.other | UAM. Instituto Teófilo Hernando de I+D del Medicamento (ITH) | es_ES |
dc.contributor.other | Instituto de Investigación del Hospital de La Princesa (IP) | es_ES |
dc.date.accessioned | 2018-08-24T12:20:43Z | |
dc.date.available | 2018-08-24T12:20:43Z | |
dc.date.issued | 2017-12-01 | |
dc.identifier.citation | Pharmacogenomics 19.1 (2018): 7-16 | en_US |
dc.identifier.issn | 1462-2416 (print) | es_ES |
dc.identifier.issn | 1744-8042 (online) | es_ES |
dc.identifier.uri | http://hdl.handle.net/10486/684692 | |
dc.description.abstract | Aims. This study evaluated the influence of pharmacogenetics in psoriatic patients treated with adalimumab and/or infliximab. Materials & methods: Prospective observational study evaluating the association of 124 polymorphisms with the response to adalimumab or infliximab (PASI75) in patients with moderate-to-severe plaque psoriasis at 3 months (n = 95) and 6 months of treatment (n = 90). Significant SNPs for univariate analysis were subjected to multivariate analysis. Results: Five SNPs were associated with PASI75 at 3 months: rs6661932 (IVL), rs2546890 (IL-12B), rs2145623 (NFKBIA), rs9304742 (ZNF816A) and rs645544 (SLC9A8). Furthermore, rs1061624 (TNFR1B) was associated with PASI75 at 6 months. Conclusion: Nevertheless, these biomarkers should be validated in large-scale studies before implementation in clinical practice. | en_US |
dc.format.extent | 27 pag. | es_ES |
dc.format.mimetype | application/pdf | en |
dc.language.iso | eng | en |
dc.publisher | Future Medicine | en_US |
dc.relation.ispartof | Pharmacogenomics | en_US |
dc.rights | © 2018 Future Medicine Ltd. | en_US |
dc.subject.other | Adalimumab | en_US |
dc.subject.other | Anti-TNF drugs | en_US |
dc.subject.other | Infliximab | en_US |
dc.subject.other | Pharmacogenetics | en_US |
dc.subject.other | Psoriasis | en_US |
dc.title | Polymorphisms associated with adalimumab and infliximab response in moderate-to-severe plaque psoriasis | en_US |
dc.type | article | en |
dc.subject.eciencia | Farmacia | es_ES |
dc.date.embargoend | 2018-12-01 | |
dc.relation.publisherversion | https://doi.org/10.2217/pgs-2017-0143 | es_ES |
dc.identifier.doi | 10.2217/pgs-2017-0143 | es_ES |
dc.identifier.publicationfirstpage | 7 | es_ES |
dc.identifier.publicationissue | 1 | es_ES |
dc.identifier.publicationlastpage | 16 | es_ES |
dc.identifier.publicationvolume | 19 | es_ES |
dc.type.version | info:eu-repo/semantics/acceptedVersion | e |
dc.rights.accessRights | openAccess | en |
dc.authorUAM | Abad Santos, Francisco (259532) | |
dc.authorUAM | Daudén Tello, Esteban (259153) | |
dc.authorUAM | Ochoa Mazarro, María Dolores (278857) | |
dc.facultadUAM | Facultad de Medicina | |
dc.institutoUAM | Instituto Teófilo Hernando de I+D del Medicamento (ITH) | |
dc.institutoUAM | Instituto de Investigación Sanitaria Hospital Universitario de La Princesa (IIS-Princesa) | |